Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1951-1960 of 2922 for cancer

Edit search filters
  1. Pembrolizumab Plus Epacadostat Alone Or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo In Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-02/ECHO-306)

    Rochester, MN

  2. A Study to Compare Whole Brain Radiotherapy and Memantine to Stereotactic Radiosurgery vs. Stereotactic Radiosurgery Alone to Treat Patients with Cancer That Has Spread to the Brain After Earlier Stereotactic Radiosurgery

    Jacksonville, FL

  3. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  4. A Study Assessing The Effectiveness And Safety Of Alpelisib Plus Fulvestrant In Men And Postmenopausal Women Who Have Advanced Breast Cancer Which Progressed On Or After Aromatase Inhibitor Treatment

    Scottsdale/Phoenix, AZ

  5. Outcomes After Secondary Cytoreductive Surgery With Or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed By Systemic Combination Chemotherapy For Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

    Rochester, MN

  6. A Study To Compare The Combination Of BMS-986504 With Pembrolizumab And Chemotherapy Versus Placebo Plus Pembrolizumab And Chemotherapy In First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study to Assess the Effectiveness and Safety of UGN-102 as a Primary Chemoablation Agent in Patients with Low Grade Non-Muscle-Invasive Bladder Cancer (LG NMIBC) at Intermediate Risk of Recurrence

    Scottsdale/Phoenix, AZ

  8. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Jacksonville, FL, Rochester, MN

  9. A Study of MPDL3280A (Anti-PD-L1 Antibody) Combined with Carboplatin and Paclitaxel , and with or without Bevacizumab, for Patients who have Stage IV Non-Squamous Non-Small Cell Lung Cancer

    Jacksonville, FL

  10. Outcomes Of Regional Consensus Treatment Guidelines For Management Of Surgery, Invasive Procedures And Control Of Hemorrhages In Patients With Bleeding Disorders; And Management Of Thrombosis And Thromboprophylaxis In Patients With Thrombophilia

    Rochester, MN

.

Mayo Clinic Footer